Preview

Sechenov Medical Journal

Advanced search

Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort studу

https://doi.org/10.47093/2218-7332.2022.376.07

Full Text:

Abstract

Aim. To evaluate antibody responses following two doses of ChAdOx1 nCoV-19 Corona vaccination in a tertiary care setting and the association of host factors like age, body mass index and comorbidities in determining this antibody response.

Materials and methods. This prospective serosurveillance study was done among healthcare workers of Jubilee Mission Medical College, vaccinated during January- April 2021. Blood samples were drawn from 170 participants after their first dose and from 156 participants after their second dose of CovishieldTM to measure the specific Ig G antibodies against the recombinant S1 subunit of the S protein of SARS-CoV-2.

Results. The median level of anti-SARS-CoV-2 Ig G antibody 28–56 days after the first dose vaccination was 3.64 S/C (1.33, 7.24) and 11.6 S/C (8.61, 14.27) after 14 days of second dose vaccination. Protective levels of anti-SARS CoV-2 Ig G antibodies (≥ 9.5 S/C) was developed by 25 participants (14.7%, 95% confidence interval: 9.8% to 20.9%) after 28–56 days of first dose of vaccination and by 109 participants (69.9%, 95% confidence interval: 62% to 77%) after 14 days of second dose. Health care workers in the age group below 60 years (p = 0.027) and without comorbidities (p = 0.079) showed higher protective Ig G levels. But on multiple logistic regression only age under 60 years was found to be statistically significant.

Conclusion. After the first dose of the ChAdOx1 nCoV-19 vaccine, the formation of Ig G antibodies was observed, the level of which increased after the second dose. Among the various associated factors studied only the age of the participants below 60 years was found to be statistically significant for protective antibody levels. Follow up studies involving larger and different ethnic population is key to decoding the antibody response especially in the elderly and high-risk groups.

About the Authors

S. K. Njarekkattuvalappil
Jubilee Mission Medical College and Research Institute
India

Swathi K. Njarekkattuvalappil, MBBS, MD, Assistant Professor, Department of Community Medicine 

Thrissur-680005, Kerala



R. Bhaskaran
Jubilee Mission Medical College and Research Institute
India

Ramesh Bhaskaran, MBBS, MD, Professor, Department of Transfusion Medicine 

Thrissur-680005, Kerala



V. Sree Raj
Jubilee Mission Medical College and Research Institute
India

Sree Raj V., MBBS, MD, Junior Resident, Department of Transfusion Medicine 

Thrissur-680005, Kerala



P. Jose
Jubilee Mission Medical College and Research Institute
India

Ponnu Jose, MBBS, MD, Assistant Professor, Department of Community Medicine 

Thrissur-680005, Kerala



Aboobacker M. Rafi
Jubilee Mission Medical College and Research Institute
India

Aboobacker M. Rafi, MBBS, MD, Assistant Professor, Department of Transfusion Medicine 

Thrissur-680005, Kerala



J. Thomas
Jubilee Mission Medical College and Research Institute
India

Joe Thomas, MBBS, MD, Professor, Department of Community Medicine 

Thrissur-680005, Kerala



S. J. Innah
Jubilee Mission Medical College and Research Institute
India

Susheela J. Innah, MBBS, MD, Professor, Department of Transfusion Medicine 

Thrissur-680005, Kerala



L. Raphael
Jubilee Mission Medical College and Research Institute
India

Lucy Raphael, MBBS, MD, Professor, Department of Community Medicine 

Thrissur-680005, Kerala



U. G. Unnikrishnan
Jubilee Mission Medical College and Research Institute
India

Uttumadathil G. Unnikrishnan, MSc, Statistician, Department of Community Medicine 

Thrissur-680005, Kerala



P. Rajmohan
Jubilee Mission Medical College and Research Institute
India

Priyanka Rajmohan, MBBS, MD, Associate Professor, Department of Community Medicine 

Thrissur-680005, Kerala



Ch. Valsan
Jubilee Mission Medical College and Research Institute
India

Chithra Valsan, MBBS, MD, Professor, Department of Microbiology 

Thrissur-680005, Kerala



P. Kuttichira
Jubilee Mission Medical College and Research Institute
India

Praveenlal Kuttichira, MBBS, MD, Principal & Professor of Psychiatry 

Thrissur-680005, Kerala



References

1. Fortner A., Schumacher D. First COVID-19 Vaccines receiving the US FDA and EMA emergency use authorization. Discoveries (Craiova, Romania). 2021 Mar 5; 9(1): e122. https://doi.org/10.15190/d.2021.1. PMID: 33969180.

2. Voysey M., Costa Clemens S.A., Madhi S.A., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6; 397(10277): 881–91. https://doi.org/10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. Erratum in: Lancet. 2021 Mar 6; 397(10277): 880. PMID: 33617777.

3. Figueiredo-Campos P., Blankenhaus B., Mota C., et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020 Dec; 50(12): 2025–40. https://doi.org/10.1002/eji.202048970. Epub 2020 Nov 10. PMID: 33084029.

4. Manners C., Larios Bautista E., Sidoti H., Lopez O.J. Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines. Cureus. 2020 Jun 1; 12(6): e8399. https://doi.org/10.7759/cureus.8399. PMID: 32499988.

5. Rafi A.M., Tomy M. M. L. J., Thomas R., et al. Serosurveillance of SARS-CoV-2 among the healthcare workers of a tertiary care teaching institution during the post lockdown phase in Central Kerala, India. Journal of Clinical and Diagnostic Research 2021; 15(7): LC13–7. https://doi.org/10.7860/jcdr/2021/48703.15154

6. Poland G.A., Ovsyannikova I.G., Kennedy R.B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14; 396(10262): 1595–606. https://doi.org/10.1016/S0140-6736(20)32137-1. Epub 2020 Oct 13. PMID: 33065034.

7. Padoan A., Bonfante F., Pagliari M., et al.Analytical and clinical performances of five immunoassays for the detection of SARSCoV-2 antibodies in comparison with neutralization activity. EBioMedicine. 2020 Dec; 62: 103101. https://doi.org/10.1016/j.ebiom.2020.103101. Epub 2020 Nov 4. PMID: 33160207.

8. Sherina N., Piralla A., Du L., et al. Persistence of SARS-CoV2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med (N Y). 2021 Mar 12; 2(3): 281–95.e4. https://doi.org/10.1016/j.medj.2021.02.001. Epub 2021 Feb 10. PMID: 33589885.

9. Isho B., Abe K.T, Zuo M., et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020 Oct 8; 5(52): eabe5511. https://doi.org/10.1126/sciimmunol.abe5511. PMID: 33033173.

10. Duysburgh E., Mortgat L., Barbezange C., et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis. 2021 Feb; 21(2): 163–164. https://doi.org/10.1016/S1473-3099(20)30943-9. Epub 2020 Dec 17. Erratum in: Lancet Infect Dis. 2020 Dec 21; Erratum in: Lancet Infect Dis. 2021 Feb; 21(2): e16. PMID: 33341124.

11. Ewer K.J., Barrett J.R., Belij-Rammerstorfer S., et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Feb; 27(2): 270–8. https://doi.org/10.1038/s41591-020-01194-5. Epub 2020 Dec 17. Erratum in: Nat Med. 2021 Jun; 27(6): 1116. PMID: 33335323.

12. Folegatti P.M., Ewer K.J., Aley P.K., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15; 396(10249): 467–78. https://doi.org/10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: Lancet. 2020 Aug 15; 396(10249): 466. Erratum in: Lancet. 2020 Dec 12;396(10266):1884. PMID: 32702298.

13. Singh A.K., Phatak S.R., Singh R., et al. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021 Oct 22; 39(44): 6492–509. https://doi.org/10.1016/j.vaccine.2021.09.055. Epub 2021 Sep 24. PMID: 34600747.

14. Hoque A., Barshan A.D., Chowdhury F.U.H., et al. Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: A prospective observational study. Infect Drug Resist. 2021 Dec 19; 14: 5491–500. https://doi.org/10.2147/IDR.S335414. PMID: 34984006.

15. Ali H., Alahmad B., Al-Shammari A.A., et al. Previous COVID-19 infection and antibody levels after vaccination. Front Public Health. 2021 Dec 1; 9: 778243. https://doi.org/10.3389/fpubh.2021.778243. PMID: 34926392.

16. Iacobucci G. COVID-19: Most UK adults had antibodies after one dose of AstraZeneca or Pfizer vaccine, data suggest. BMJ. 2021 May 18; 373: n1274. https://doi.org/10.1136/bmj.n1274.PMID: 34006531.

17. Wei J., Stoesser N., Matthews P.C., et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021 Sep; 6(9): 1140–9. https://doi.org/10.1038/s41564-021-00947-3. Epub 2021 Jul 21. PMID: 34290390.

18. Müller L., Andrée M., Moskorz W., et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis. 2021 Dec 6; 73(11): 2065–72. https://doi.org/10.1093/cid/ciab381. PMID: 33906236.

19. Gustafson C.E., Kim C., Weyand C.M., Goronzy J.J. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020 May; 145(5): 1309–21. https://doi.org/10.1016/j.jaci.2020.03.017. PMID: 32386655.

20. Lampasona V., Secchi M., Scavini M., et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020 Dec; 63(12): 2548–58. https://doi.org/10.1007/s00125-020-05284-4. Epub 2020 Oct 8. PMID: 33029657.

21. Ramasamy M.N., Minassian A.M., Ewer K.J., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19; 396(10267): 1979–93. https://doi.org/10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19. Erratum in: Lancet. 2021 Dec 19; 396(10267): 1978. Erratum in: Lancet. 2021 Apr 10; 397(10282): 1350. PMID: 33220855.


Supplementary files

1. STROBE Statement—Checklist of items that should be included in reports of cohort studies
Subject
Type Исследовательские инструменты
Download (92KB)    
Indexing metadata
2. Similarity check (Antiplagiat)
Subject
Type Исследовательские инструменты
Download (390KB)    
Indexing metadata

Review

Views: 162


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)